You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Obtaining approval for your patient’s treatment may require your institution to complete several steps, including conducting a thorough benefits investigation to determine if a prior authorization or medical exception is needed. Our Gamifant Patient Services team is available to help explain these processes at 833-597-6530.
Sobi has developed a library of resources to help you and your institution navigate the insurance approval process for Gamifant.Gamifant Start Form
A guide to review the processDownload
Information about different types of coverageDownload
Details about the process and submission of documentation to gain approvalDownload
It is the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for those products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, and payment policies.
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.1-4
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.5
Gamifant is given as an intravenous infusion twice per week until the patient no longer requires therapy for the treatment of HLH or until hematopoietic stem cell transplantation (HSCT) is performed.5
Download the Start Form now or contact Gamifant Patient Services at 833-597-6530.